Clinical trial · no report yet · Phase 3
ASCENT-04
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
- NCT05382286 ↗
- Active not recruiting
- Gilead Sciences
- 324 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 134 | |
| YouTube | 104 | |
| Podcasts | 74 | |
| X videos | 12 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Triple Negative Breast Cancer; PD-L1 Positive
- Interventions
- Sacituzumab Govitecan-hziy; Pembrolizumab; Paclitaxel; nab-Paclitaxel; Gemcitabine; Carboplatin
- Arms
- Sacituzumab Govitecan-hziy (SG) + Pembrolizumab · Experimental
- Pembrolizumab + Treatment of Physician's Choice (TPC) · Active comparator
- Enrollment
- 443
- Primary outcomes
- Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
- Sponsor
- Gilead Sciences with Merck Sharp & Dohme LLC
- Start
- Jul 25, 2022
- Primary completion
- Feb 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05382286 · updated Sep 18, 2025
Publications
linked from the registry- Tolaney SM, de Azambuja E, Kalinsky K, Loi S, Kim SB, Yam C, Rapoport B, Im SA, Pistilli B, Mchayleh W, Cescon DW, Watanabe J, Banuelas MAL, Freitas-Junior R, Salvador Bofill J, Afshari M, Gary D, Wang L, Lai C, Schmid P; ASCENT-04/KEYNOTE-D19 Clinical Trial Investigators. Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. N Engl J Med. 2026 Jan 22;394(4):354-366. doi: 10.1056/NEJMoa2508959. PubMed 41564397